Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
214% and keeps going
MGRX; INDEED!!! (Hey, all seriousness aside, this one is a minimum 10-bagger today!!! But look at the competition from that freak-show @MGOL!!!)
MGRX chiks like those big SD guns…lol
MGRX: Hey, Admiral TW-0122, you know that I have BASHED this Firm many times in the past behind the TYPE of lurid ads they were running, but I NEVER mocked their substantive PRODUCT. Hey, Bro, I myself have been using it for MONTHS now. Heck, last Friday night, at a swingin' singles bar over here in (balmy) San Diego, CA, the hot chick in the bar security cam below almost got me BUSTED, Dude!!! And only 5-minutes after I had gulped a FIST FULL of MRGX's new pills!!!!
ED to weight loss get hard then thin for the ladies a duo combo…lol
Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth and hormone replacement therapies is excited to announce the development of proprietary oral formulations of Semaglutide (“Slim”) and Tirzepatide (“Trim”) to aid in weight management. These innovative drugs, currently available predominantly in injectable form, have demonstrated remarkable efficacy in clinical trials. MangoRx’s new oral formulations are poised to revolutionize the weight loss market and capture significant market share.
The GLP-1 receptor agonists’ market, including both Semaglutide and Tirzepatide, is projected to reach over $164 billion in combined revenue by 2032, based on Visible Alpha consensus, ramping up from $37.9 billion in 2023. These are record-breaking revenues for any drug class in the history of drug development.
The oral formulations of Semaglutide and Tirzepatide are set to capture a significant share of this market, offering a convenient alternative to injections. Semaglutide, marketed under the brand names Ozempic® and Wegovy®, and Tirzepatide, marketed as Mounjaro® and Zepbound®, are both glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs have demonstrated impressive weight loss results in clinical trials. In a recent study, patients taking Semaglutide achieved an average weight loss of 15.2% over one year, while those taking Tirzepatide experienced an average weight loss of 15.7%. The oral formulations of Semaglutide and Tirzepatide are designed for daily consumption and are expected to provide similar weight loss benefits without the need for regular injections.
Patient preference studies consistently show a significant majority in favor of oral medications over injectables. This preference is anticipated to drive higher adoption rates and expand the existing market. The shift to an oral formulation offers a more accessible and convenient option for patients, potentially increasing adherence and overall treatment success.
“We are thrilled to introduce ‘Slim’ and ‘Trim’, MangoRx’s oral formulations of Semaglutide and Tirzepatide, to the weight loss market,” said Jacob Cohen, CEO and Co-Founder of MangoRx. “Our goal is to provide patients with a convenient and effective way to manage their weight and improve their overall health. We believe that these oral formulations have the potential to significantly impact the lives of millions of people worldwide.”
MangoRx plans to have the products available for customers on the company’s telemedicine platform in the beginning of the 3rd quarter with ‘Slim’ and ‘Trim’ competitively priced at $299/month and $399/month, respectively. MangoRx is committed to advancing the treatment of obesity and related conditions and is dedicated to improving the lives of patients worldwide.
Wee doggie Granny, were up 118% at this moment
MGRX spike on new out +122%
nice bounce back after hitting .15's low in march
MGRX: This circus sideshow carnival routine could still NOT get its PRICE 'UP' --- no sexual innuendo intended --- even if DONALD TRUMP had just tried their stuff & made World News Tonight by proclaiming that he got his first 'HARD-ON' since his last date with 'STORMY DANIELS' over 4-years ago!!!
the super bowl lie
What specifically makes it a “scam”?
i guess by now you know its a scam
https://www.otcmarkets.com/filing/html?id=17286151&guid=nrd-kpJOCvxHJth
purposes:
1. To approve an Amendment to the Company’s Certificate of Formation, as amended to approve a reverse stock split of the Company’s outstanding common stock. Stockholders are being asked to approve an amendment to our Certificate of Formation, as amended, to effect a reverse stock split of our issued and outstanding shares of our common stock, par value $0.0001 per share, by a ratio of between one-for-two to one-for-fifty inclusive, with the exact ratio to be set at a whole number to be determined by our Board of Directors or a duly authorized committee thereof in its discretion, at any time after approval of the amendment and prior to [_________], 2025 (the “Reverse Split Proposal”).
I'll pray you find your way...for now, you get the ignore button.
$MGRX - NEWS OUT! MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth
February 20 2024 - 09:00AM
Alert
Print
Share On Facebook
Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug (‘Mango’), its hair growth product (‘GROW’), and its FDA approved oral testosterone replacement therapy (TRT), ‘PRIME’, by MangoRx, powered by Kyzatrex®️, is excited to announce that it has officially launched its direct-to-clinics sales division offering doctors and medical practitioners the ability to prescribe MangoRx products to their patients directly from their offices, clinics and brick and mortar locations. The Company also reports that it has successfully onboarded its first medical health and wellness clinic based in Dallas, TX last week.
The Company believes that this direct-to-clinics initiative will assist in fueling a greater amount of recurring revenues while at the same time reducing customer acquisition costs (CACs) associated with traditional digital marketing strategies. The first of its kind within MangoRx’s direct competitor group, the Company will be deploying a boots-on-the-ground sales force with a mission to penetrate existing brick and mortar men’s health and wellness clinics across the United States, including but not limited to Med Spas, Low Testosterone clinics, and specialty doctors’ offices.
Jonathan Arango, MangoRx’s Co-Founder and President noted, “we are very excited for the launch of this direct-to-clinics initiative as this has been a part of our business plan and in the works since the 4th quarter of 2023. Since we have launched our Mango ED products, many doctors have approached us asking how they could prescribe Mango to their existing patients. This led us to design our newly custom-built prescribing system that allows for the practitioner to prescribe MangoRx products – including our newly launched ‘PRIME’, by MangoRx, powered by Kyzatrex®️ – while at the same time acquiring a new MangoRx customer within our ecosystem.”
MangoRx transactions are currently being initiated by consumers seeking MangoRx’s products. This newly developed prescribing system will now allow for prescribing doctors and medical practitioners to initiate the transaction for the sale of MangoRx’s products. The Company will be activating a website where providers and clinics can visit to complete the onboarding process to qualify as a MangoRx preferred provider.
Jacob Cohen, MangoRx’s Co-Founder and CEO noted, “our initial research has shown that some of these providers prescribe as many as 6,000 to 7,000 ED prescriptions per year from within their offices or clinics. This amount, compounded with the opportunity for them to also prescribe ‘PRIME’, by MangoRx, powered by Kyzatrex®️, presents an exponential growth opportunity especially given PRIME’s $199 monthly subscription rate. We are confident that this new initiative will fuel our revenue growth and have a further impact on making MangoRx a household name.”
About MangoRx
MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.
To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.
JOUKOUKOU22 WHERE ARE YOU ?? ARE YOU COUNTING YOUR PROFITS YET ??
JOUKOUKOU....HOW ARE YOU ?? HOLDING STRONG HERE ???
ARE YOU GONNA RELOAD AT 10 CENTS OR LOWER ??
Still holding here from $0.35 braw…
HOW CAN I TRADE WITHOUT YOUR PUMP RECOMMENDATION ??
HOW ABOUT ANOTHER RECOMMENDATION ?? GIVE YOU ANOTHER SHOT AT IT
You keep posting I'll keep making money..
IGPK
CGAC
DLOC
Jesus man trade something and make some money will you.... instead of worrying about me..
Having a particularly nice week myself how about you??
LMMFAO
Clearly you're obsessed 90% of your posts are to me and I'm not even paying attention to you but somebody told me you were posting to me..
HOW ABOUT A NEW CODE NAME : TRUCKJOUKOUKOU SINCE THE CAR AIN'T WORKING !!
WHAT DO YOU THINK ?? YOU NEED TO RESTART THE PUMP !!
JOUKOUKOU...WHERE ARE YOU HIDING THIS MORNIG, MGRX NEEDS YOUR SUPPORT GIRL !!
YOU KNOW THE SUPERBOWL THING DID NOT WORK OUT LAST TIME IN THE PUMPING OPERATION;
I HAVE ANOTHER IDEA FOR YOU : WHY DON'T YOU TRY THE UPCOMING MARCH MADNESS CHAMPIONSHIP !!
HOW ABOUT THAT ?? NEVER KNOW......GIVE IT A SHOT !!
JOUKOUKOU....WHERE ARE YOU !!
MGRX NEEDS SOME PUMPING THIS MORNING, MORONS ARE WAITING FOR YOU !!
GO AT IT GIRL !! DON'T BE SHY !!
YOU NEED TO ASK THE NO.ONE PUMPER HERE MISS CARJOUKOUKOU TO KEEP PUMPING !!
SHE'S GOOD AT IT !!
$MGRX - holding up well here. Setting up for that pop to close gap. IMO
ONE DESCRIBE ONLY THEMSELVES !! GOT IT SENIORITA PITA !! I THINK YOU NEED A MARGERITTA !!
OK THEN; YOU'RE ONE OF THOSE PUMPERS !! KEEP PUMPING.....NEXT STOP 10 PENNIES.
Might look into decaf
Does MGRX have a Muffler Bearing issue too!
THERE IS NO GOOD NEWS COMING BUDDY; WHAT WE HAVE ON THIS BOARD
IS A BUNCH OF PUMPERS, SAME PERSON WITH DIFFERENT ALIASES POSTING
CREATING THE IMPRESSION OF MANY INDIVIDUALS .
16th post to me..LMAO
Some are just children masquerading as adults..
$MGRX - any good news and this goes.
WOW...AND I MEAN WOW....HOW QUICKLY WE CHANGE OUR TUNE !!
PUMP AND PUMP AND NOW THAT YOU SOLD INTO THE PUMP......SUDDENLY THIS
COMPANY CAN'T GET IT'S ACT TOGETHER. AMAZING...SIMPLY AMAZING HOW THICK IS YOUR BULLSHIT.
I don’t short stocks. That PR today reminded me of how the CEO operates. I was giving him another chance after what he did to his last ticker. You’ll understand soon enough imo.
No matter what I don’t trust Jacob 1 bit. He’s your typical penny stock CEO in a Nasdaq shell
Yes it was closed based on an 8K released by the company.
The underwriters had a warrant to purchase shares and they did and probably were sold. Who knows
They did a filing for an S1 to raise money. They never said they raised enough money and stated that the S1 was officially closed now did they? So obviously it’s still going on so you have investors using it as an ATM until then
Why was this never an issue before you jumped in prior to the superbowl weekend?
Now it’s all of a sudden an issue?
Are you short on this stock?
They already did an offering not long ago. So where does this dilution talk come from
It’s getting pushed down and manipulated no doubt
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4775
|
Created
|
03/17/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |